Author

M. D. Shortridge

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

G. Varani· 2 shared B. Chaubey· 1 shared G. Calin· 1 shared G. L. Olsen· 1 shared H. J. Zhang· 1 shared T. Pavelitz· 1 shared V. Vidalala· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

7 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

G. Varani

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivApr 30, 2022

Drug-like small molecules that inhibit expression of the oncogenic microRNA-21

M. D. Shortridge, B. Chaubey, H. J. Zhang…·G. Varani

This study identifies small molecules that inhibit miR-21 maturation, showing specific anti-proliferative effects in cancer cells without affecting kinases or receptors.

DOI 10.1021/acschembio.2c00502

humanproteomics

𝕏 PostBluesky

BiochemistrybioRxivPreprintJan 20, 2022

The kinase inhibitor Palbociclib is a potent and specific RNA-binding molecule

M. D. Shortridge, V. Vidalala, G. Varani

The paper identifies Palbociclib as an RNA-binding molecule with nM affinity for HIV-1 TAR RNA, demonstrating that RNA-targeting drugs can achieve potent and specific binding.

DOI 10.1101/2022.01.20.477126

experimental assayhost-pathogen & immune response

𝕏 PostBluesky